Merck seeks additional Januvia approvals

Share this article:
Merck has filed applications with the FDA for two additional uses for its diabetes treatment Januvia. Merck is seeking approval for Januvia for the added indications as an adjunct to diet and exercise, in combination with metformin as initial therapy to improve glycemic control; and as an adjunct to diet and exercise, as add-on therapy to a sulfonylurea plus metformin when dual therapy does not provide adequate glycemic control. Januvia is currently approved for use as a monotherapy and as add-on therapy to either metformin or thiazolidinediones, to improve blood sugar control in patients with type 2 diabetes when diabetes when diet and exercise are not enough. Januvia was approved in October 2006. Fourth quarter sales of the drug came in at $42 million.
Share this article:

Email Newsletters

More in News

Star Group merges with Vox Medica, Calcium NYC

Star Group merges with Vox Medica, Calcium NYC

The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...